Wealth Enhancement Advisory Services, LLC Protagonist Therapeutics, Inc Transaction History
Wealth Enhancement Advisory Services, LLC
- $61.1 Billion
- Q3 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 3,511 shares of PTGX stock, worth $277,755. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,511Holding current value
$277,755% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
298Shares Held
67MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$488 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$456 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$455 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$337 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$257 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.88B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...